Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors

European Journal of Medicinal Chemistry

Volumn 95, Issue , 2015, Pages 127-135

  Zhang, Xuan ^a   Kong, Yannan ^a   Zhang, Jie ^b   Su, Mingbo ^c   Zhou, Yubo ^c   Zang, Yi ^c   Li, Jia ^c   Chen, Yi ^b   Fang, Yanfen ^a   Zhang, Xiongwen ^a   Lu, Wei ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c Guo Shou Jing Rd S   (China)

Author keywords

Colchicine; Dual inhibitor; HDAC; Hybrid; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; METHYL 3 [[2 [(TERT BUTOXYCARBONYL)AMINO] 5 (THIOPHEN 2 YL)PHENYL]CARBAMOYL]BENZOATE; METHYL 3 [[2 [(TERT BUTOXYCARBONYL)AMINO]PHENYL]CARBAMOYL]BENZOATE; METHYL 4 [[2 [(TERT BUTOXYCARBONYL)AMINO] 5(THIOPHEN 2 YL)PHENYL]CARBAMOYL]BENZOATE; METHYL 4-[[2 [(TERT BUTOXYCARBONYL)AMINO]PHENYL]CARBAMOYL]BENZOATE; TERT BUTYL [2 [3 (CHLOROMETHYL)BENZAMIDO] 4 (THIOPHEN 2 YL)PHENYL]CARBAMATE; TERT BUTYL [2 [3 (CHLOROMETHYL)BENZAMIDO]PHENYL]CARBAMATE; TERT BUTYL [2 [4 (CHLOROMETHYL)BENZAMIDO] 4 (THIOPHEN 2 YL)PHENYL]CARBAMATE; TERT BUTYL [2 [4 (CHLOROMETHYL)BENZAMIDO]PHENYL]CARBAMATE; TUBULIN; UNCLASSIFIED DRUG; COLCHICINE; HISTONE DEACETYLASE; TUBULIN MODULATOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE; COLORECTAL CANCER CELL LINE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; GASTRIC CANCER CELL LINE; HCT116 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CANCER CELL LINE; MICROTUBULE ASSEMBLY; MTT ASSAY; OSTEOSARCOMA CELL LINE; PANCREATIC CANCER CELL LINE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; EVALUATION STUDY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; COLCHICINE; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 84925641143     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.03.035     Document Type: Article

References (39)

1. Internaional Agency for Research on Cancer, World Cancer Report 2014, World Health Organization, Geneva, 2014.
2. L. Costantino, D. Barlocco, Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry? Future Med. Chem. 5 (2013) 5-7.
3. M.S. Kim, M. Blake, J.H. Baek, G. Kohlhagen, Y. Pommier, F. Carrier, Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA, Cancer Res. 63 (2003) 7291-7300.
4. F. Bruzzese, M. Rocco, S. Castelli, E. Di Gennaro, A. Desideri, A. Budillon, Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis, Mol. Cancer Ther. 8 (2009) 3075-3087.
5. R.L. Bevins, S.G. Zimmer, It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells, Cancer Res. 65 (2005) 6957-6966.
6. M. Ocker, A. Alajati, M. Ganslmayer, S. Zopf, M. Luders, D. Neureiter, E.G. Hahn, D. Schuppan, C. Herold, The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells, J. Cancer Res. Clin. Oncol. 131 (2005) 385-394.
7. B. Sarcar, S. Kahali, P. Chinnaiyan, Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines, J. Neuro-Oncol. 99 (2010) 201-207.
8. M. Dokmanovic, C. Clarke, P.A. Marks, Histone deacetylase inhibitors: overview and perspectives, Mol. Cancer Res. 5 (2007) 981-989.
9. H.Y. Lin, C.S. Chen, S.P. Lin, J.R. Weng, C.S. Chen, Targeting histone deacetylase in cancer therapy, Med. Res. Rev. 26 (2006) 397-413.
10. M.J. Lee, Y.S. Kim, S. Kummar, G. Giaccone, J.B. Trepel, Histone deacetylase inhibitors in cancer therapy, Curr. Opin. Oncol. 20 (2008) 639-649.
11. C.S. Chen, S.C. Weng, P.H. Tseng, H.P. Lin, C.S. Chen, Histone acetylationindependent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes, J. Biol. Chem. 280 (2005) 38879-38887.
12. K. Nepali, S. Sharma, M. Sharma, P. Bedi, K. Dhar, Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids, Eur. J. Med. Chem. 77 (2014) 422-487.
13. K.A. Papavassiliou, A.G. Papavassiliou, Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment, Expert Opin. Invest. Drugs (2013) 1-4.
14. H. Wang, B.W. Dymock, New patented histone deacetylase inhibitors, Expert Opin. Ther. Pat. 19 (2009) 1727-1757.
15. A. Saito, T. Yamashita, Y. Mariko, Y. Nosaka, K. Tsuchiya, T. Ando, T. Suzuki, T. Tsuruo, O. Nakanishi, A synthetic inhibitor of histone deacetylase, MS-27- 275, with marked in vivo antitumor activity against human tumors, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4592-4597.
16. R.D. Glick, S.L. Swendeman, D.C. Coffey, R.A. Rifkind, P.A. Marks, V.M. Richon, M.P. La Quaglia, Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma, Cancer Res. 59 (1999) 4392-4399.
17. L.M. Butler, D.B. Agus, H.I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H.T. Thaler, R.A. Rifkind, P.A. Marks, V.M. Richon, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo, Cancer Res. 60 (2000) 5165-5170.
18. A.K. Oyelere, P.C. Chen, W. Guerrant, S.C. Mwakwari, R. Hood, Y. Zhang, Y. Fan, Non-peptide macrocyclic histone deacetylase inhibitors, J. Med. Chem. 52 (2009) 456-468.
19. X. Cai, H.X. Zhai, J. Wang, J. Forrester, H. Qu, L. Yin, C.J. Lai, R. Bao, C. Qian, Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-Nhydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer, J. Med. Chem. 53 (2010) 2000-2009.
20. C.J. Lai, R. Bao, X. Tao, J. Wang, R. Atoyan, H. Qu, D.G. Wang, L. Yin, M. Samson, J. Forrester, B. Zifcak, G.X. Xu, S. DellaRocca, H.X. Zhai, X. Cai, W.E. Munger, M. Keegan, C.V. Pepicelli, C. Qian, CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity, Cancer Res. 70 (2010) 3647-3656.
21. S. Mahboobi, S. Dove, A. Sellmer, M. Winkler, E. Eichhorn, H. Pongratz, T. Ciossek, T. Baer, T. Maier, T. Beckers, Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases, J. Med. Chem. 52 (2009) 2265-2279.
22. S. Mahboobi, A. Sellmer, M. Winkler, E. Eichhorn, H. Pongratz, T. Ciossek, T. Baer, T. Maier, T. Beckers, Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity, J. Med. Chem. 53 (2010) 8546-8555.
23. F. Thaler, Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications, Pharm. Pat. Anal. 1 (2012) 75-90.
24. X. Zhang, M. Su, Y. Chen, J. Li, W. Lu, The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors, Molecules 18 (2013) 6491-6503.
25. X. Zhang, J. Zhang, L.J. Tong, Y. Luo, M.B. Su, Y. Zang, J. Li, W. Lu, Y. Chen, The discovery of colchicine-SAHA hybrids as a new class of antitumor agents, Bioorg. Med. Chem. 21 (2013) 3240-3244.
26. X. Zhang, B. Bao, X. Yu, L. Tong, Y. Luo, Q. Huang, M. Su, L. Sheng, J. Li, H. Zhu, B. Yang, X. Zhang, Y. Chen, W. Lu, The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase, Bioorg. Med. Chem. 21 (2013) 6981-6995.
27. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, R. Pazdur, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist 12 (2007) 1247-1252.
28. C. Grant, F. Rahman, R. Piekarz, C. Peer, R. Frye, R.W. Robey, E.R. Gardner, W.D. Figg, S.E. Bates, Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors, Expert Rev. Anticancer Ther. 10 (2010) 997-1008.
29. S.C. Mwakwari, V. Patil, W. Guerrant, A.K. Oyelere, Macrocyclic histone deacetylase inhibitors, Curr. Top. Med. Chem. 10 (2010) 1423-1440.
30. R.M. Poole, Belinostat: first global approval, Drugs 74 (2014) 1543-1554.
31. M. Paris, M. Porcelloni, M. Binaschi, D. Fattori, Histone deacetylase inhibitors: from bench to clinic, J. Med. Chem. 51 (2008) 1505-1529.
32. C.H. Arrowsmith, C. Bountra, P.V. Fish, K. Lee, M. Schapira, Epigenetic protein families: a new frontier for drug discovery, Nat. Rev. Drug Discovery 11 (2012) 384-400.
33. J.H. Kim, E.K. Yoon, H.J. Chung, S.Y. Park, K.M. Hong, C.H. Lee, Y.S. Lee, K. Choi, Y. Yang, K. Kim, I.H. Kim, p53 acetylation enhances Taxol-induced apoptosis in human cancer cells, Apoptosis 18 (2013) 110-120.
34. N.H. Chobanian, V.L. Greenberg, J.M. Gass, C.P. Desimone, J.R. Van Nagell, S.G. Zimmer, Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status, Anticancer Res. 24 (2004) 539-545.
35. V. Zuco, M. De Cesare, R. Cincinelli, R. Nannei, C. Pisano, N. Zaffaroni, F. Zunino, Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo, PloS One 6 (2011) -29085.
36. J.D. Bagnato, A.L. Eilers, R.A. Horton, C.B. Grissom, Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin, J. Org. Chem. 69 (2004) 8987-8996.
37. L. Cosentino, M. Redondo-Horcajo, Y. Zhao, A.R. Santos, K.F. Chowdury, V. Vinader, Q.M. Abdallah, H. Abdel-Rahman, J.r.m. Fournier-Dit-Chabert, S.D. Shnyder, Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties, J. Med. Chem. 55 (2012) 11062-11066.
38. O.M. Moradei, T.C. Mallais, S. Frechette, I. Paquin, P.E. Tessier, S.M. Leit, M. Fournel, C. Bonfils, M.C. Trachy-Bourget, J.H. Liu, T.P. Yan, A.H. Lu, J. Rahil, J. Wang, S. Lefebvre, Z.M. Li, A.F. Vaisburg, J.M. Besterinan, Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity, J. Med. Chem. 50 (2007) 5543-5546.
39. M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs, Nat. Rev. Cancer 4 (2004) 253-265.